Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions

Increased focus on non-animal models for COVID-19 and non-COVID lung research

Laura Gribaldo, Killian Hurley, Pieter Hiemstra, Catherine Greene
European Respiratory Journal 2021 57: 2004267; DOI: 10.1183/13993003.04267-2020
Laura Gribaldo
1European Commission, Joint Research Center (JRC), Ispra, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Killian Hurley
2Dept of Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pieter Hiemstra
3Dept of Pulmonology, Leiden University Medical Center, Leiden, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Pieter Hiemstra
Catherine Greene
4Dept of Clinical Microbiology, Royal College of Surgeons in Ireland, Dublin, Ireland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Catherine Greene
  • For correspondence: CMGreene@rcsi.ie
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

A recent report from the European Commission highlights strategies for the development of safe and efficacious therapies for respiratory diseases, especially those that exploit non-animal methods and recapitulate the mechanistic basis of human disease https://bit.ly/2Vk3xfA

To the Editor:

Horizon Europe is a major stakeholder in the immediate future of lung research. As such, we believe it is worthwhile drawing the attention of the European Respiratory Journal readership to the recent publication by Hynes et al. [1] on Advanced Non-animal Models in Biomedical Research: Respiratory Tract Diseases. This report from the European Commission's Joint Research Centre EU Reference Laboratory (EURL ECVAM), and its accompanying dataset [2], identifies well-established current and emerging in vitro, in silico and ex vivo non-animal models for respiratory disease modelling, and reinforces the concept of “reduce, refine, or replace” animals used for scientific purposes. The 3R approach is not only embraced by the European Commission, but also the respiratory research community, as evidenced by many European Respiratory Society publications as well as frequent ERS Congress sessions and research seminars on the topic.

The EURL ECVAM study, prepared with the partnership of external experts in the field, involved a systematic review of peer-reviewed scientific literature. Over 21 000 abstracts (11 636 non-cancer and 9421 cancer) were scanned for relevant non-animal models of respiratory disease culminating in a knowledge base containing detailed descriptions of 284 non-animal models currently or recently being used for respiratory disease research. Briefly, the review shows that while simple models are still prominent and have their uses, in the past 5 years research focus has been shifting towards increasingly sophisticated bioengineering approaches that recapitulate human lung development, anatomy and physiology in vitro. Such novel approaches hold promise as blueprints for modelling human-relevant diseases and can be used not only to elucidate mechanism of disease, but also to aid in the development of new therapies and responses thereto. The findings from the study are freely available to download from the EURL ECVAM Collection in the JRC Data Catalogue, together with a JRC Technical Report that describes the review methodology and presents the main findings [1, 2]. Ideally, this knowledge base will serve as a means to explore the strengths and limitations of both animal and non-animal models used in biomedical research; to stimulate healthy scientific debate; to challenge mindsets; and ultimately to pave the way for doing better science. Key conclusions of the work are summarised in table 1. Its overarching aim is to bridge methods and disciplines in order to improve biomedical science for the benefit of patients and society.

View this table:
  • View inline
  • View popup
TABLE 1

Key summary points related to uptake, development and standardisation of non-animal models for respiratory disease research

Respiratory diseases, including asthma, COPD, cystic fibrosis, pulmonary fibrosis and lung cancer represent a significant health burden to society. However, the majority of preclinical studies of new therapeutics for chronic lung diseases fail to identify effective treatments that are ultimately translated to the clinic, with over 90% of new drug programmes not progressing to market due to lack of efficacy or unexplained toxicity. This failure may be due in part to the use of preclinical models that do not fully recapitulate the complexity of human disease, are inherently hindered by interspecies differences, employ cells which are not specifically affected by the target disease in patients, or do not represent the genetic background of affected patients. Emerging non-animal preclinical models, such as lung-on-a-chip models, three-dimensional spheroid and organoid systems derived from primary and stem cell origins, and human tissue cultures such as precision cut lung slices, offer the opportunity to simulate human disease in vitro and ex vivo in a more robust and patient-specific manner [3–5]. Thereby, these novel investigative platforms provide important mechanistic information about respiratory diseases and identify targets for novel treatments.

The current coronavirus disease 2019 (COVID-19) crisis also highlights the need for better patient- and disease-relevant lung models. In the relatively short period since the identification of SARS-CoV-2 as the causative virus of COVID-19, important progress has been made in advancing our knowledge about the disease using in vitro culture methods and in silico approaches. A variety of approaches have been used for a range of purposes, including the study of epithelial cell tropism of the virus [6], effectivity of antiviral drugs [7], and application of organoids [8] and lung-on-chip models for COVID-19 modelling [9]. In addition to using primary lung epithelial cells isolated from lung tissue, human induced pluripotent stem cell-derived alveolar type 2 cells have been used to obtain insight into the transcriptional response of these cells to infection, and their potential use for drug testing [10]. Whereas these examples used epithelial culture models, other studies have used cells from other organs to delineate their involvement in COVID-19. Careful matching of the research question to the culture model used and an awareness of the limitations intrinsic to any model remains essential.

In conclusion, this report from the European Commission highlights research strategies for the development of safe and efficacious new therapies for well-known and emerging respiratory diseases especially those that exploit non-animal methods and recapitulate the mechanistic basis of human disease. Such approaches are widely welcomed and in due course are likely to outnumber and outperform animal studies.

Shareable PDF

Supplementary Material

This one-page PDF can be shared freely online.

Shareable PDF ERJ-04267-2020.Shareable

Footnotes

  • Conflict of interest: L. Gribaldo has nothing to disclose.

  • Conflict of interest: K. Hurley has nothing to disclose.

  • Conflict of interest: P. Hiemstra reports grants from the Dutch Society for the Replacement of Animal Testing, outside the submitted work.

  • Conflict of interest: C. Greene has nothing to disclose.

  • Received November 19, 2020.
  • Accepted November 20, 2020.
  • Copyright ©ERS 2021
http://creativecommons.org/licenses/by-nc/4.0/

This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.

References

  1. ↵
    1. Hynes J,
    2. Marshall L,
    3. Adcock I, et al.
    Advanced Non-animal Models in Biomedical Research: Respiratory Tract Diseases. EUR 30334 EN. Publications Office of the European Union, Luxembourg, 2020.
  2. ↵
    European Commission. Joint Research Centre Data Catalogue. EURL ECVAM Review of Non-animal Models in Biomedical Research: Respiratory Tract Diseases. https://data.jrc.ec.europa.eu/dataset/176d71e6-5082-4b29-8472-b719f6bda323
  3. ↵
    1. Bonniaud P,
    2. Fabre A,
    3. Frossard N, et al.
    Optimising experimental research in respiratory diseases: an ERS statement. Eur Respir J 2018; 51: 1702133. doi:10.1183/13993003.02133-2017
    OpenUrlAbstract/FREE Full Text
    1. Hiemstra PS,
    2. Tetley TD,
    3. Janes SM
    . Airway and alveolar epithelial cells in culture. Eur Respir J 2019; 54: 1900742. doi:10.1183/13993003.00742-2019
    OpenUrlFREE Full Text
  4. ↵
    1. Alsafadi HN,
    2. Uhl FE,
    3. Pineda RH, et al.
    Applications and approaches for three-dimensional precision-cut lung slices. Disease modeling and drug discovery. Am J Respir Cell Mol Biol 2020; 62: 681–691. doi:10.1165/rcmb.2019-0276TR
    OpenUrl
  5. ↵
    1. Hou YJ,
    2. Okuda K,
    3. Edwards CE, et al.
    SARS-CoV-2 reverse genetics reveals a variable infection gradient in the respiratory tract. Cell 2020; 182: 429–446.e14. doi:10.1016/j.cell.2020.05.042
    OpenUrl
  6. ↵
    1. Hoffmann M,
    2. Kleine-Weber H,
    3. Schroeder S, et al.
    SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020; 181: 271–280.e8. doi:10.1016/j.cell.2020.02.052
    OpenUrlCrossRefPubMed
  7. ↵
    1. Lamers MM,
    2. Beumer J,
    3. van der Vaart J, et al.
    SARS-CoV-2 productively infects human gut enterocytes. Science 2020; 69: 50–54. doi:10.1126/science.abc1669
    OpenUrl
  8. ↵
    1. Tang H,
    2. Abouleila Y,
    3. Si L, et al.
    Human organs-on-chips for virology. Trends Microbiol 2020; 28: 934–946. doi:10.1016/j.tim.2020.06.005
    OpenUrl
  9. ↵
    1. Huang J,
    2. Hume AJ,
    3. Abo KM, et al.
    SARS-CoV-2 infection of pluripotent stem cell-derived human lung alveolar type 2 cells elicits a rapid epithelial-intrinsic inflammatory response. Cell Stem Cell 2020; 27: 962–973.
    OpenUrl
PreviousNext
Back to top
View this article with LENS
Vol 57 Issue 1 Table of Contents
European Respiratory Journal: 57 (1)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Increased focus on non-animal models for COVID-19 and non-COVID lung research
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Increased focus on non-animal models for COVID-19 and non-COVID lung research
Laura Gribaldo, Killian Hurley, Pieter Hiemstra, Catherine Greene
European Respiratory Journal Jan 2021, 57 (1) 2004267; DOI: 10.1183/13993003.04267-2020

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Increased focus on non-animal models for COVID-19 and non-COVID lung research
Laura Gribaldo, Killian Hurley, Pieter Hiemstra, Catherine Greene
European Respiratory Journal Jan 2021, 57 (1) 2004267; DOI: 10.1183/13993003.04267-2020
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Shareable PDF
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

Agora

  • Airway immune responses to COVID-19 vaccination in COPD patients
  • Wider access to rifapentine-based regimens is needed for TB care globally
  • Association between immunosuppressants and outcomes of COVID-19
Show more Agora

Correspondence

  • Clinical outcomes of bronchiectasis in India
  • Reply: Clinical outcomes of bronchiectasis in India
  • Risk factors for disease progression in fibrotic hypersensitivity pneumonitis
Show more Correspondence

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society